Achaogen Executives
Achaogen employs about 42 people. The company is managed by 31 executives with a total tenure of roughly 247 years, averaging almost 7.0 years of service per executive, having 1.35 employees per reported executive. Analysis of Achaogen's management performance can provide insight into the firm performance.
| Kenneth Hillan CEO President CEO, Chief Medical Officer, Director |
| Karl Kjelstad CEO CEO |
Achaogen |
Achaogen Management Team Effectiveness
Achaogen's management efficiency ratios could be used to measure how well Achaogen manages its routine affairs as well as how well it operates its assets and liabilities.Achaogen Workforce Comparison
Achaogen is number one stock in number of employees category among related companies. The total workforce of Biotechnology industry is presently estimated at about 105,957. Achaogen adds roughly 42.0 in number of employees claiming only tiny portion of stocks in Biotechnology industry.
Achaogen Notable Stakeholders
An Achaogen stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Achaogen often face trade-offs trying to please all of them. Achaogen's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Achaogen's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Kenneth Hillan | President CEO, Chief Medical Officer, Director | Profile | |
| Karl Kjelstad | CEO | Profile | |
| Kristian Rokke | Chairman of the Board | Profile | |
| Lone Schroder | Deputy Chairman of the Board | Profile | |
| Bryan Roberts | Chairman of the Board | Profile | |
| Paal Johnsen | Executive Vice President - Investment Director | Profile | |
| Lee Swem | Senior Vice President Chief Scientific Officer | Profile | |
| Leif Borge | CFO | Profile | |
| Tobin Schilke | CFO, Principal Financial Officer and Principal Accounting Officer | Profile | |
| Liz Bhatt | COO | Profile | |
| Blake Wise | COO | Profile | |
| Elizabeth Bhatt | COO | Profile | |
| Christopher Walsh | Independent Director | Profile | |
| Sarah Ryan | Director | Profile | |
| Halley Gilbert | Director | Profile | |
| John Smither | Independent Director | Profile | |
| Stian Sjolund | Director, Employee Representative | Profile | |
| Gregory Stea | Director | Profile | |
| Kent Lieginger | Director | Profile | |
| Asle Halvorsen | Director, Employee Representative | Profile | |
| Alan Colowick | Director | Profile | |
| John Doyle | Director | Profile | |
| Oyvind Eriksen | Director | Profile | |
| Henning Jensen | Director, Employee Representative | Profile | |
| Michael Fischbach | Director | Profile | |
| Karen Bernstein | Independent Director | Profile | |
| Kathryn Baker | Director | Profile | |
| Zeryn Sarpangal | Principal Financial Officer, Principal Accounting Officer and VP of HR and Corporate Affairs | Profile | |
| Janet Dorling | Chief Commercial Officer | Profile | |
| Ian Friedland | Chief Medical Officer | Profile | |
| Gary Loeb | General Counsel | Profile |
Achaogen Workforce Analysis
Traditionally, organizations such as Achaogen use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Achaogen within its industry.Achaogen Manpower Efficiency
Return on Achaogen Manpower
| Revenue Per Employee | 207.9K | |
| Revenue Per Executive | 281.6K | |
| Net Loss Per Employee | 4.4M | |
| Net Loss Per Executive | 6M | |
| Working Capital Per Employee | 1.4M | |
| Working Capital Per Executive | 1.8M |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the Achaogen information on this page should be used as a complementary analysis to other Achaogen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Other Consideration for investing in Achaogen Stock
If you are still planning to invest in Achaogen check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Achaogen's history and understand the potential risks before investing.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Stocks Directory Find actively traded stocks across global markets | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |